| Identification | More | [Name]
5-(4,5-dimethoxy-2-methylbenzyl)-2,4-diaminopyrimidine | [CAS]
6981-18-6 | [Synonyms]
5-(4,5-dimethoxy-2-methylbenzyl)-2,4-diaminopyrimidine
ORMETHOPRIM
ORMETOPRIM
ORMETOPRIN
OMP
L-Ascorbic Phosphate Magnesium
2,4-Diamino-5-(6-methylveratryl)pyrimidine
5-(4,5-Dimethoxy-2-methylbenzyl)pyrimidine-2,4-diamine
NSC-95072
Ro 5-9754 | [EINECS(EC#)]
230-246-6 | [Molecular Formula]
C14H18N4O2 | [MDL Number]
MFCD00057747 | [Molecular Weight]
274.32 | [MOL File]
6981-18-6.mol |
| Chemical Properties | Back Directory | [Melting point ]
231.0 to 235.0 °C | [Boiling point ]
521.5±60.0 °C(Predicted) | [density ]
1.223±0.06 g/cm3(Predicted) | [storage temp. ]
0-6°C | [solubility ]
Chloroform (Slightly, Heated), DMSO (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
7.11±0.10(Predicted) | [color ]
Off-White | [Water Solubility ]
Water: Insoluble | [λmax]
287nm(CHCl3)(lit.) | [Stability:]
Hygroscopic | [CAS DataBase Reference]
6981-18-6(CAS DataBase Reference) | [EPA Substance Registry System]
Ormetoprim (6981-18-6) |
| Hazard Information | Back Directory | [Uses]
It is a potent and selective inhibitor of bacterial dihydrofolate reductase, the enzyme responsible for the NADPH-dependent reduction of 7,8-dihydrofolate to 5,6,7,8-tetrahydrofolate. Antibacterial. | [Uses]
It is a potent and selective inhibitor of bacterial dihydrofolate reductase, the enzyme responsible for the NADPH-dependent reduction of 7,8-dihydrofolate to 5,6,7,8-tetrahydrofolate. Antibacterial.This compound is a contaminant of emerging concern (CECs). | [Definition]
ChEBI: 5-[(4,5-dimethoxy-2-methylphenyl)methyl]pyrimidine-2,4-diamine is a dimethoxybenzene. | [Synthesis Reference(s)]
Journal of Medicinal Chemistry, 14, p. 462, 1971 DOI: 10.1021/jm00287a029 | [in vivo]
Ormetoprim (8.3 mg/kg; i.p.) exhibits absorption half-life (5.4 h), elimination half-life (7.5 h) and Cmax (1.2±0.2 μg/mL)[3].
Ormetoprim (8.3 mg/kg; p.o.) exhibits absorption half-life (3.9 h), elimination half-life (3.9 h), Cmax (1.6±0.4 μg/mL) and oral availability (78.5%) relative to intraperitoneal administration[3]. | Animal Model: | Hybrid striped bass (565-805 g)[3] | | Dosage: | 50 mg/kg Sulfadimethoxine and Ormetoprim in a 5:1 ratio (Pharmacokinetic Analysis) | | Administration: | I.p. and p.o. administration | | Result: | I.p.: t1/2(elim)=7.5 h; t1/2(abs)=5.4 h; Cmax=1.2 μg/mL.
P.o.: t1/2(elim)=3.9 h; t1/2(abs)=3.9 h; Cmax=1.6 μg/mL; F=78.5%.
|
|
|
|